http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Biocompatible Peritoneal Dialysis Solution Preserves Residual Renal Function
Kim, Sejoong,Oh, Kook-Hwan,Oh, Jieun,Kim, Soo Jin,Chung, Wookyung,Song, Young Rim,Na, Ki Young,Oh, Yun Kyu,Ahn, Curie,Kim, Sung Gyun,Tan, Kathryn C.B. S. Karger AG 2012 American journal of nephrology Vol.36 No.4
<P>Abstract</P><P><B><I>Background/Aims:</I></B> The long-term effects of biocompatible peritoneal dialysis (PD) solution on residual renal function (RRF), inflammation, adipokines and metabolic acidosis are controversial. We evaluated the effects of biocompatible PD solution in continuous ambulatory PD (CAPD) patients for an additional 12-month period. <B><I>Method:</I></B> Among 91 incident patients who started CAPD with either biocompatible PD solution (Balance®, Fresenius; LS, n = 48) or conventional PD solution (CAPD/DPCA®, Fresenius; CS, n = 43), 63 patients, who were followed for 12 months, were enrolled and followed for an additional 12 months. <B><I>Results:</I></B> After 24 months of treatment, the glomerular filtration rate (GFR) of the LS group was twofold higher compared to the CS group (33.5 ± 30.7 vs. 16.3 ± 17.9 l/week/1.73 m<SUP>2</SUP>, respectively, p <I>= </I>0.021). In a subgroup of patients with an initial GFR >2 ml/min/1.73 m<SUP>2</SUP>, the GFR of the LS group was significantly higher than the rate of the CS group after 24 months (43.7 ± 30.5 vs. 18.6 ± 19.0 l/week/1.73 m<SUP>2</SUP>, respectively, p = 0.042). Over a 24-month period, effluent cancer antigen-125 levels were significantly increased in the LS group compared to the CS group, while effluent interleukin-6 levels did not differ between the two groups. The serum tCO<SUB>2</SUB> levels were consistently higher in the LS group compared to the CS group. <B><I>Conclusions:</I></B> We found that the effect of LS on preserving RRF may be maintained over a 24-month treatment period in CAPD patients, and LS use may have other benefits, such as the correction of metabolic acidosis.</P><P>Copyright © 2012 S. Karger AG, Basel</P>
( Se-yun Kim ),( Yu Ho Lee ),( Yang-gyun Kim ),( Ju-young Moon ),( Ho Jun Chin ),( Sejoong Kim ),( Dong Ki Kim ),( Suhnggwon Kim ),( Jung Hwan Park ),( Sung Joon Shin ),( Bum Soon Choi ),( Chun Soo Li 대한신장학회 2018 Kidney Research and Clinical Practice Vol.37 No.4
Background: Several epidemiologic studies have suggested that the urine sodium excretion (USE) can be estimated in lieu of performing 24-hour urine collection. However, this method has not been verified in patients with chronic kidney disease (CKD) or in an interventional study. The purpose of this study was to evaluate the usefulness of estimating USE in a prospective low-salt diet education cohort (ESPECIAL). Methods: A new formula was developed on the basis of morning fasting urine samples from 228 CKD patients in the ESPECIAL cohort. This formula was compared to the previous four formulas in the prediction of 24-hour USE after treatment with olmesartan and low-salt diet education. Results: Most previously reported formulas had low predictability of the measured USE based on the ESPECIAL cohort. Only the Tanaka formula showed a small but significant bias (9.8 mEq/day, P < 0.05) with a low correlation (r = 0.34). In contrast, a new formula showed improved bias (-0.1 mEq/day) and correlation (r = 0.569) at baseline. This formula demonstrated no significant bias (-1.2 mEq/day) with the same correlation (r = 0.571) after 8 weeks of treatment with olmesartan. Intensive low-salt diet education elicited a significant decrease in the measured USE. However, none of the formulas predicted this change in the measured urine sodium after diet adjustment. Conclusion: We developed a more reliable formula for estimating the USE in CKD patients. Although estimating USE is applicable in an interventional study, it may be unsuitable for estimating the change of individual sodium intake in a low-salt intervention study.
Oh, Yun Jung,Kim, Myounghee,Lee, Hajeong,Lee, Jung Pyo,Kim, Ho,Kim, Sejoong,Oh, Kook-Hwan,Joo, Kwon Wook,Lim, Chun Soo,Kim, Suhnggwon,Kim, Yon Su,Kim, Dong Ki Springer International ; Oxford University Press 2012 Nephrology, dialysis, transplantation Vol.27 No.6
<P>Vitamin D deficiency is known as an important risk factor for mortality in patients with chronic kidney disease (CKD). Nevertheless, the association of renal function itself with vitamin D status or serum 25-hydroxyvitamin D (25OHD) level has not been investigated thoroughly.</P>
Metabolic Acidosis and Long-Term Clinical Outcomes in Kidney Transplant Recipients
Park, Seokwoo,Kang, Eunjeong,Park, Sehoon,Kim, Yong Chul,Han, Seung Seok,Ha, Jongwon,Kim, Dong Ki,Kim, Sejoong,Park, Su-Kil,Han, Duck Jong,Lim, Chun Soo,Kim, Yon Su,Lee, Jung Pyo,Kim, Young Hoon American Society of Nephrology 2017 Journal of the American Society of Nephrology Vol.28 No.6
( Sejoong Kim ),( Jong Cheol Jeong ),( Shin Young Ahn ),( Kibbeum Doh ),( Dong-chan Jin ),( Ki Young Na ) 대한신장학회 2019 Kidney Research and Clinical Practice Vol.38 No.1
Background: Unlike patterns observed in the general population, obesity is associated with better survival among hemodialysis patients, which could be explained by reverse causation or illness-related weight loss. However, the time-varying effect of body mass index (BMI) on hemodialysis survival has not been investigated. Therefore, this study investigated the time-varying effect of BMI on mortality after starting hemodialysis. Methods: In the present study, we examined Korean Society of Nephrology data from 16,069 adult patients who started hemodialysis during or after the year 2000. Complete survival data were obtained from Statistics Korea. Survival analysis was performed using Cox regression and a non-proportional hazard fractional polynomial model. Results: During the median follow-up of 8.6 years, 9,272 patients (57.7%) died. Compared to individuals with normal BMI (18.5-24.9 kg/m2), the underweight group (< 18.5 kg/m2) had a higer mortality hazard ratio (HR, 1.292; 95% confidence interval [CI], 1.203-1.387; P < 0.001) and the overweight group (25.0-29.9 kg/m2) had a lower mortality HR (0.904; 95% CI, 0.829-0.985; P = 0.022). The underweight group had increasing HRs during the first 3 to 7 years after starting hemodialysis, which varied according to age group. The young obese group (< 40 years old) had a U-shaped temporal trend in their mortality HRs, which reflected increased mortality after 7 years. Conclusion: The obese hemodialysis group had better survival during the early post-dialysis period, although the beneficial effect of obesity disappeared 7 years after starting hemodialysis. The young obese group also had an increased mortality HR after 7 years.
Effects of colchicine on renal fibrosis and apoptosis in obstructed kidneys
( Sejoong Kim ),( Eun Sook Jung ),( Jeonghwan Lee ),( Nam Ju Heo ),( Ki Young Na ),( Jin Suk Han ) 대한내과학회 2018 The Korean Journal of Internal Medicine Vol.33 No.3
Background/Aims: Colchicine is an established drug for microtubule stabilization that may reduce tissue injury. No data were available that its effects may depend on the dosage of colchicine. We investigated the anti-fibrotic and apoptotic effects of various dose of colchicine in a unilateral ureteral obstruction (UUO) model. Methods: Thirty-six Sprague-Dawley rats were randomly assigned into six groups. Two sham groups were divided into a vehicle-treated or colchicine-treated group (100 μg/kg/day). Four UUO groups were treated with either vehicle or three different doses of colchicine for 7 days (30, 60, and 100 μg/kg/day, intraperitoneally). All of the animals were sacrificed on day 7. Results: Colchicine treatment diminished acetylated α-tubulin and tumor growth factor-β immunoreactivities in the cortical area of the 7-day obstructed kidneys, which was in dose dependent manner. Colchicine attenuated tubulointerstitial damage and apoptosis in both cortical and medullary area, and beneficial effects of colchicine therapy were dramatically shown at the higher dosage of colchicine. The expression levels of cleaved caspase-3, ED-1, and fibronectin were decreased in UUO animals. Conclusions: We found that the proper dosage of colchicine may have anti-fibrotic and anti-apoptotic effects in obstructed kidneys. For clinical applications, an optimal dose of colchicine should be evaluated to maximize the prevention of renal disease progression.